Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma
©2014 AACR..
Glioblastoma is the most common and aggressive histologic subtype of brain cancer with poor outcomes and limited treatment options. Here, we report the selective overexpression of the protein arginine methyltransferase PRMT5 as a novel candidate theranostic target in this disease. PRMT5 silences the transcription of regulatory genes by catalyzing symmetric dimethylation of arginine residues on histone tails. PRMT5 overexpression in patient-derived primary tumors and cell lines correlated with cell line growth rate and inversely with overall patient survival. Genetic attenuation of PRMT5 led to cell-cycle arrest, apoptosis, and loss of cell migratory activity. Cell death was p53-independent but caspase-dependent and enhanced with temozolomide, a chemotherapeutic agent used as a present standard of care. Global gene profiling and chromatin immunoprecipitation identified the tumor suppressor ST7 as a key gene silenced by PRMT5. Diminished ST7 expression was associated with reduced patient survival. PRMT5 attenuation limited PRMT5 recruitment to the ST7 promoter, led to restored expression of ST7 and cell growth inhibition. Finally, PRMT5 attenuation enhanced glioblastoma cell survival in a mouse xenograft model of aggressive glioblastoma. Together, our findings defined PRMT5 as a candidate prognostic factor and therapeutic target in glioblastoma, offering a preclinical justification for targeting PRMT5-driven oncogenic pathways in this deadly disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:74 |
|---|---|
| Enthalten in: |
Cancer research - 74(2014), 6 vom: 15. März, Seite 1752-65 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yan, Fengting [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.05.2014 Date Revised 21.10.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1158/0008-5472.CAN-13-0884 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM234745266 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM234745266 | ||
| 003 | DE-627 | ||
| 005 | 20231224101925.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/0008-5472.CAN-13-0884 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0782.xml |
| 035 | |a (DE-627)NLM234745266 | ||
| 035 | |a (NLM)24453002 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yan, Fengting |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.05.2014 | ||
| 500 | |a Date Revised 21.10.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a ©2014 AACR. | ||
| 520 | |a Glioblastoma is the most common and aggressive histologic subtype of brain cancer with poor outcomes and limited treatment options. Here, we report the selective overexpression of the protein arginine methyltransferase PRMT5 as a novel candidate theranostic target in this disease. PRMT5 silences the transcription of regulatory genes by catalyzing symmetric dimethylation of arginine residues on histone tails. PRMT5 overexpression in patient-derived primary tumors and cell lines correlated with cell line growth rate and inversely with overall patient survival. Genetic attenuation of PRMT5 led to cell-cycle arrest, apoptosis, and loss of cell migratory activity. Cell death was p53-independent but caspase-dependent and enhanced with temozolomide, a chemotherapeutic agent used as a present standard of care. Global gene profiling and chromatin immunoprecipitation identified the tumor suppressor ST7 as a key gene silenced by PRMT5. Diminished ST7 expression was associated with reduced patient survival. PRMT5 attenuation limited PRMT5 recruitment to the ST7 promoter, led to restored expression of ST7 and cell growth inhibition. Finally, PRMT5 attenuation enhanced glioblastoma cell survival in a mouse xenograft model of aggressive glioblastoma. Together, our findings defined PRMT5 as a candidate prognostic factor and therapeutic target in glioblastoma, offering a preclinical justification for targeting PRMT5-driven oncogenic pathways in this deadly disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a RNA, Small Interfering |2 NLM | |
| 650 | 7 | |a ST7 protein, human |2 NLM | |
| 650 | 7 | |a TP53 protein, human |2 NLM | |
| 650 | 7 | |a Tumor Suppressor Protein p53 |2 NLM | |
| 650 | 7 | |a Tumor Suppressor Proteins |2 NLM | |
| 650 | 7 | |a PRMT5 protein, human |2 NLM | |
| 650 | 7 | |a EC 2.1.1.319 |2 NLM | |
| 650 | 7 | |a Protein-Arginine N-Methyltransferases |2 NLM | |
| 650 | 7 | |a EC 2.1.1.319 |2 NLM | |
| 700 | 1 | |a Alinari, Lapo |e verfasserin |4 aut | |
| 700 | 1 | |a Lustberg, Mark E |e verfasserin |4 aut | |
| 700 | 1 | |a Martin, Ludmila Katherine |e verfasserin |4 aut | |
| 700 | 1 | |a Cordero-Nieves, Hector M |e verfasserin |4 aut | |
| 700 | 1 | |a Banasavadi-Siddegowda, Yeshavanth |e verfasserin |4 aut | |
| 700 | 1 | |a Virk, Selene |e verfasserin |4 aut | |
| 700 | 1 | |a Barnholtz-Sloan, Jill |e verfasserin |4 aut | |
| 700 | 1 | |a Bell, Erica Hlavin |e verfasserin |4 aut | |
| 700 | 1 | |a Wojton, Jeffrey |e verfasserin |4 aut | |
| 700 | 1 | |a Jacob, Naduparambil K |e verfasserin |4 aut | |
| 700 | 1 | |a Chakravarti, Arnab |e verfasserin |4 aut | |
| 700 | 1 | |a Nowicki, Michal O |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Lapalombella, Rosa |e verfasserin |4 aut | |
| 700 | 1 | |a Datta, Jharna |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Bo |e verfasserin |4 aut | |
| 700 | 1 | |a Gordon, Kate |e verfasserin |4 aut | |
| 700 | 1 | |a Haseley, Amy |e verfasserin |4 aut | |
| 700 | 1 | |a Patton, John T |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Porsha L |e verfasserin |4 aut | |
| 700 | 1 | |a Ryu, John |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Xiaoli |e verfasserin |4 aut | |
| 700 | 1 | |a Mo, Xiaokui |e verfasserin |4 aut | |
| 700 | 1 | |a Marcucci, Guido |e verfasserin |4 aut | |
| 700 | 1 | |a Nuovo, Gerard |e verfasserin |4 aut | |
| 700 | 1 | |a Kwon, Chang-Hyuk |e verfasserin |4 aut | |
| 700 | 1 | |a Byrd, John C |e verfasserin |4 aut | |
| 700 | 1 | |a Chiocca, E Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Chenglong |e verfasserin |4 aut | |
| 700 | 1 | |a Sif, Said |e verfasserin |4 aut | |
| 700 | 1 | |a Jacob, Samson |e verfasserin |4 aut | |
| 700 | 1 | |a Lawler, Sean |e verfasserin |4 aut | |
| 700 | 1 | |a Kaur, Balveen |e verfasserin |4 aut | |
| 700 | 1 | |a Baiocchi, Robert A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer research |d 1945 |g 74(2014), 6 vom: 15. März, Seite 1752-65 |w (DE-627)NLM000001740 |x 1538-7445 |7 nnns |
| 773 | 1 | 8 | |g volume:74 |g year:2014 |g number:6 |g day:15 |g month:03 |g pages:1752-65 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1158/0008-5472.CAN-13-0884 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 74 |j 2014 |e 6 |b 15 |c 03 |h 1752-65 | ||